| Literature DB >> 26284649 |
Bingbo Wang1, Lin Gao1, Qingfang Zhang1, Aimin Li2, Yue Deng3, Xingli Guo1.
Abstract
BACKGROUND: The complexity of biological systems motivates us to use the underlying networks to provide deep understanding of disease etiology and the human diseases are viewed as perturbations of dynamic properties of networks. Control theory that deals with dynamic systems has been successfully used to capture systems-level knowledge in large amount of quantitative biological interactions. But from the perspective of system control, the ways by which multiple genetic factors jointly perturb a disease phenotype still remain.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26284649 PMCID: PMC4540569 DOI: 10.1371/journal.pone.0135491
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1A schematic diagram of diversified control paths.
(a): a linear dynamic system with adjacency matrix A and input matrix B. (b): the Kalman’s controllability rank condition, if rank(Q ) = n, this system is controllable. (c): for the underlying network, propose a maximum-matching set (MMSet) to assess the structural controllability. Links of the MMSet are highlighted by red. (d): for a network G(A), differentiated MMSet M and M , marked by red, construct diversified control path sets. Disease genes are marked by purple and their perturbation ranges are indicated by shadow areas.
Fig 2The perturbation influences of disease genes of the Tuberculosis (MIM:107470).
(a): A CPSet of the partial human regulatory network, the MMSet links are highlighted by red, the disease gene IFNGR1 and IFNG are marked by purple, their perturbation ranges are circled with red and blue dotted lines respectively. (b): Another differentiated CPSet. (c): the perturbation influences of IFNGR1 and IFNG are marked by red and blue shadow respectively.
Instances for the perturbation influence of disease gene.
| Disease | Disease gene | Perturbation influence | Common Gene Ontology term |
|---|---|---|---|
| Thrombocythemia(MIM: 187950) | TPO | JAK3, STAT1, SOCS1, IL20RB, TYK2, STAT4, SOCS4, CSF2RB, BAX | JAK-STAT cascade, Growth hormone receptor signaling pathway,Cytokine-mediated signaling pathway, … |
| JAK2 | STAT1, SOCS1, JAK3, IL20RB, STAT2, SOCS7, CRLF2 | ||
| MPL | JAK3, STAT1, SOCS1, IL20RB, TYK2, STAT4, SOCS4, CSF2RB, BAX | ||
| Immunodeficiency(MIM: 610163) | CD3E | ZAP70, CD3D, CD3Z, NCR3, FCER1G, NCR1, FCER1A, MS4A2, FCGR3 | Innate immune response,Regulation of immune response,Regulation of immune effector process,Regulation of defense response,… |
| CD3G | ZAP70, CD3Z, NCR3, FCER1G, NCR1, FCER1A, MS4A2, FCGR3 |
The ranks of known disease genes for three instances.
| Alzheimer Disease (MIM:104300) | |||||
| Disease gene | Rank | Disease gene | Rank | Disease gene | Rank |
| APP | 7 | PLAU | 4 | A2M | 2 |
| NOS3 | 5 | PSEN1 | 3 | APOE | 1 |
| Breast cancer (MIM:114480) | |||||
| Disease gene | Rank | Disease gene | Rank | Disease gene | Rank |
| CDH1 | 6 | TP53 | 4 | ATM | 2 |
| PIK3CA | 5 | PPM1D | 3 | RAD53 | 1 |
| Colorectal cancer (MIM: 114500) | |||||
| Disease gene | Rank | Disease gene | Rank | Disease gene | Rank |
| CTNNB1 | 19 | PIK3CA | 16 | TP53 | 9 |
| AXIN2 | 2 | SRC | 3 | TGFBR2 | 4 |
| APC | 1 | NRAS | 7 | BAX | 18 |
| CCND1 | 5 | BRAF | 6 | PLA2G2A | 10 |
| EP300 | 13 | DCC | 14 | FGFR3 | 17 |
| BUB1 | 12 | BUB1B | 11 | BCL10 | 8 |
The top ranked candidate genes for some instances.
| Disease | Candidate Gene | Rank |
|---|---|---|
| Alzheimer Disease (MIM:104300) | LRP1 | 6 |
| Alzheimer Disease (MIM:104300) | BACE1 | 17 |
| Ovarian cancer (MIM: 167000) | PRKC1 | 4 |
| Ovarian cancer (MIM: 167000) | EGF | 5 |
| Diabetes Mellitus, Type 2 (MIM:125853) | AQP7 | 23 |
| Leukemia (MIM:601626) | PIM2 | 13 |
| Leukemia (MIM:601626) | NFKB1 | 26 |
| Colorectal cancer (MIM:114500) | PECAM1 | 15 |
| Amyloidosis (MIM:105200) | APBB1 | 1 |
Fig 3Comparison in performance between our method and PRINCE.
A plot of recall versus rank threshold, rank threshold k% means that the gene was ranked within top k%.
Enrichment analysis of causal genes in Alzheimer Disease.
| Metabolic pathway | P-value | Expected number of genes | Number of genes | Gene |
|---|---|---|---|---|
| hsa04610: Complementand coagulation cascades | 4.69e-08 | 0.381904 | 8 | PLAUR, PLG, F2, SERPINE1, F13B, FGA, F13A1, F11 |
| hsa05010: Alzheimer's disease | 6.04e-04 | 0.636507 | 5 | LRP1, BACE2, GAPDH, BACE1, LPL |
| hsa04210: Apoptosis | 2.60e-03 | 0.879537 | 6 | AKT2, AKT1, AKT3, PRKACG, NFKB1, PRKX |
| hsa04914: Progesterone-mediated oocyte maturation | 1.59e-02 | 0.856391 | 5 | AKT2, AKT1, AKT3, PRKACG, PRKX |
| hsa05142: Chagas disease | 2.14e-02 | 0.960547 | 5 | AKT2, AKT1, AKT3, SERPINE1, NFKB1 |
Enrichment analysis of causal genes in Diabetes Mellitus, Type 2.
| Metabolic pathway | P-value | Expected number of genes | Number of genes | Gene |
|---|---|---|---|---|
| hsa04930: Type II diabetes mellitus | 3.75e-09 | 0.302998 | 8 | PKLR, PIK3R3, PIK3R2, PIK3R1, PIK3R5, PIK3CG, PIK3CB, PIK3CD |
| hsa04960: Aldosterone-regulated sodium reabsorption | 5.43e-09 | 0.208311 | 7 | PIK3R3, PIK3R2, PIK3R1, PIK3R5, PIK3CG, PIK3CB, PIK3CD |
| hsa04910: Insulin signaling pathway | 1.12e-08 | 1.13624 | 11 | PKLR, PTPN1, EXOC7, TRIP10, PIK3R3, PIK3R2, PIK3R1, PIK3R5, PIK3CG, PIK3CB, PIK3CD |
| hsa04070: Phosphatidylinositol signaling system | 3.11e-08 | 0.284061 | 7 | PIK3R3, PIK3R2, PIK3R1, PIK3R5, PIK3CG, PIK3CB, PIK3CD |
| hsa04150: mTOR signaling pathway | 1.79e-07 | 0.369279 | 7 | PIK3R3, PIK3R2, PIK3R1, PIK3R5, PIK3CG, PIK3CB, PIK3CD |
Enrichment analysis of causal genes in Leukemia.
| Metabolic pathway | P-value | Expected number of genes | Number of genes | Gene |
|---|---|---|---|---|
| hsa05221: Acute myeloid leukemia | 1.51e-07 | 0.462914 | 8 | PIM2, PIM1, RELA, NFKB1, PIK3R2, PIK3CG, PIK3CB, PIK3CD |
| hsa04662: B cell receptor signaling pathway | 3.41e-06 | 0.530247 | 7 | RELA, NFKB1, VAV2, PIK3R2, PIK3CG, PIK3CB, PIK3CD |
| hsa05220: Chronic myeloid leukemia | 3.41e-06 | 0.521831 | 7 | SHC2, RELA, NFKB1, PIK3R2, PIK3CG, PIK3CB, PIK3CD |
| hsa05212: Pancreatic cancer | 3.41e-06 | 0.513414 | 7 | ARHGEF6, RELA, NFKB1, PIK3R2, PIK3CG, PIK3CB, PIK3CD |
| hsa04062: Chemokine signaling pathway | 2.83e-05 | 1.08574 | 8 | SHC2, RELA, NFKB1, VAV2, PIK3R2, PIK3CG, PIK3CB, PIK3CD |
Fig 4Analysis results for robustness of our method.
(a) The AUC of 2-fold cross validation for prioritization of oncogenes in the cancer signaling map. (b) The AUC of 5-fold cross validation for prioritization of oncogenes in the cancer signaling map. (c) The AUC of 10-fold cross validation for prioritization of oncogenes in the cancer signaling map. (d) The stability of perturbation influence of the regulatory network. (e) The stability of perturbation influence of the cancer signaling map.
The top ranked candidate genes for Breast cancer in Cancer Signaling Map.
| Breast cancer (MIM:114480) | |||||
|---|---|---|---|---|---|
| Gene | Rank | Number of mutation samples | Gene | Rank | Number of mutation samples |
| APC | 1 | 8 | FGFR | 11 | 4 |
| ATM | 2 | 20 | GR | 12 | 3 |
| p53 | 3 | 265 | PDGFRA | 13 | 4 |
| PI3K | 4 | 2 | JAK3 | 14 | 6 |
| CDH1 | 5 | 58 | JAK1 | 15 | 4 |
| DNAPK | 6 | 13 | HCK | 16 | 1 |
| p300 | 7 | 8 | VDR | 17 | 1 |
| p14ARF | 8 | 2 | TEC | 18 | 3 |
| TWIST | 9 | 2 | MEK5 | 19 | 2 |
| SHC | 10 | 1 | PLCy | 20 | 0 |
Fig 5Sketch of prediction results for Breast cancer in Cancer Signaling Map.
5 known disease genes are highlighted by red color, 15 top ranked potential causal genes are highlighted by magenta color and the genes in the diversified control paths of disease genes are highlighted by purple color.